Hepatic Encephalopathy Market Report 2026

Hepatic Encephalopathy Market Overview

• Hepatic Encephalopathy market size has reached to $1.8 billion in 2025 • Expected to grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Prevalence Of Liver Diseases Fuels Growth In The Hepatic Encephalopathy Market • Market Trend: Innovative Drug Development Drives Competition In The Hepatic Encephalopathy Market • North America was the largest region in 2025.

What Is Covered Under Hepatic Encephalopathy Market?

Hepatic encephalopathy is a condition characterized by a decline in brain function resulting from severe liver disease. It is a reversible syndrome of impaired brain function in patients with advanced liver diseases. Treating hepatic encephalopathy (HE) involves managing the underlying liver disease, reducing ammonia levels in the blood and addressing neurological symptoms. The main drug types of hepatic encephalopathy are antibiotics, laxatives, l-ornithine, l-aspartate and others. Antibiotics are a class of medications that are used to treat bacterial infections and helps lower the overall ammonia load in the body, which can contribute to the neurological symptoms associated with hepatic encephalopathy. The various route of administration including oral, intravenous and rectal which are distributed through various distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies.

What Is The Hepatic Encephalopathy Market Growth Forecast?

The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing demand for advanced therapeutics, increasing liver transplant procedures, rising focus on reducing hospitalization rates, expansion of digital monitoring tools, increased investments in hepatology research. Major trends in the forecast period include increasing adoption of targeted drug therapies, growing use of combination treatment regimens, rising focus on early diagnosis and monitoring, expansion of hospital-based treatment protocols, enhanced patient-centric care approaches.

Global Hepatic Encephalopathy Market Segmentation

1) By Drug Class: Antibiotics, Laxatives 2) By Route Of Administration: Oral, Intravenous, Rectal  3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Subsegments: 1) By Antibiotics: Rifaximin, Neomycin 2) By Laxatives: Lactulose, Polyethylene Glycol

What Are The Drivers Of The Hepatic Encephalopathy Market?

The growing prevalence of liver diseases is expected to propel the growth of the hepatic encephalopathy market going forward. Liver disease is a medical condition affecting the liver and impairing its function. Liver disease treatments such as hepatic encephalopathy can alleviate symptoms, slow disease progression, improve liver function and reduce hepatic encephalopathy occurrences by improving the management of underlying conditions, potentially reducing frequency and severity and enhancing patients' overall quality of life. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, hospital admission rates for liver disease have continued to increase, reaching 155.2 per 100,000 population (with a range of 152.9 to 157.5) in the financial year ending 2023, up from 150.6 (148.2 to 152.9) the previous year. Therefore, the growing prevalence of liver diseases drives the hepatic encephalopathy industry. Increasing healthcare expenditures are anticipated to propel the growth of the hepatic encephalopathy market. Healthcare expenditures refer to the total amount spent on healthcare-related services, products, and activities within a specified period, typically on an individual, community, national, or global level. Higher healthcare expenditures can positively impact hepatic encephalopathy treatment options by facilitating advancements in diagnosis, treatment, awareness, and patient care. For instance, in April 2025, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure grew by 6.5% in nominal terms between 2023 and 2024, compared with growth of 6.3% in 2023. Therefore, increasing healthcare expenditure will drive the growth of the hepatic encephalopathy industry.

Key Players In The Global Hepatic Encephalopathy Market

Major companies operating in the hepatic encephalopathy market are Salix Pharmaceuticals, Bausch Health Companies, Norgine, Lupin, Sun Pharmaceutical Industries, Dr Reddys Laboratories, Cipla, Teva Pharmaceutical Industries, Mylan, Torrent Pharmaceuticals, Amneal Pharmaceuticals, Zydus Lifesciences, Aurobindo Pharma, Intas Pharmaceuticals, Alkem Laboratories, Alembic Pharmaceuticals, Wockhardt, Hetero Drugs, Cadila Pharmaceuticals, Abbott India

Global Hepatic Encephalopathy Market Trends and Insights

Major companies operating in the hepatic encephalopathy market are developing innovative drugs to treat hepatic encephalopathy to gain competitive advantages and strengthen their position in the market. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, developed the novel GR3027 (golexanolone) to treat hepatic encephalopathy. This is an orally administered small molecule and a GABAA-receptor-modulating steroid antagonist (GAMSA) designed to antagonize positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is being investigated for HE. The trial is being conducted for CHE in Phases I/IIa.

Regional Outlook

North America was the largest region in the hepatic encephalopathy market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hepatic Encephalopathy Market?

The hepatic encephalopathy market consists of sales of lactulose, neomycin and zinc supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hepatic Encephalopathy Market Report 2026?

The hepatic encephalopathy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatic encephalopathy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.